½ÃÀ庸°í¼­
»óǰÄÚµå
1462910

¼¼°è Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024³â-2032³â)

Therapeutic Nuclear Medicine Market, By Type, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: AnalystView Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® 303 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 12¾ï 3,200¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2024³âºÎÅÍ 2032³â¿¡ °ÉÃÄ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 4.5%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå - ½ÃÀå ¿ªÇÐ

¸¸¼º Áúȯ Áõ°¡´Â ½ÃÀå ¼ö¿ä¸¦ ÃËÁø

¾Ï, È£Èí±â Áúȯ, ½Å°æ Áúȯ, ´ë»ç Áúȯ, ½ÉÇ÷°ü Áúȯ µîÀÇ ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ ¼¼°èÀûÀ¸·Î Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸²ÇÁÁ¾ ¿¬±¸ Àç´Ü¿¡ µû¸£¸é, ¸²ÇÁÁ¾Àº ¹Ì±¹ ¼ºÀÎ ¹× ¼Ò¾Æ¿¡¼­ °¡Àå ºó¹øÇÑ ¾ÏÀÌ¸ç ¿¬°£ 100¸¸ ¸í ÀÌ»óÀÌ Áø´ÜµÇ°í ÀÖ½À´Ï´Ù. Global Burden of DiseasesÀÇ º¸°í¼­¿¡ µû¸£¸é ½ÉÀ庴Àº ÁÖ¿ä »ç¸Á ¿øÀÎ Áß ÇϳªÀ̸ç 2018³â »ç¸ÁÀÚ ¼ö´Â ¾à 1,800¸¸ ¸íÀÔ´Ï´Ù. °Ô´Ù°¡ ¾à 3,500¸¸ ¸íÀÌ ½ÉÀå °ü·Ã ÁúȯÀ¸·Î °íÅë¹Þ°í ÀÖÀ¸¸ç, ÀÌ´Â Ä¡·á¿ë ÇÙÀÇÇп¡ ´ëÇÑ ¼ö¿ä¸¦ ²ø¾î¿Ã¸®°í ÀÖ½À´Ï´Ù.

Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

¿ì¸®ÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ½ÃÀåÀº ¿¹Ãø ±â°£(2024³â-2032³â)¿¡ ¾à 4.5%ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

À¯Çüº°·Î ¥â¹æ»çü°¡ ¿¹Ãø±â°£¿¡ ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÀ¿ë ºÐ¾ßº°·Î ¿¹Ãø ±â°£ µ¿¾È Á¾¾çÇÐÀÌ ½ÃÀå ¼ºÀåÀ» À̲ø °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÖÁ¾ ¿ëµµº°·Î º´¿øÀº ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ¸ÅÃâÀ» ¼±µµ

Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°è Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀåÀº À¯Çü, ¿ëµµ, ÃÖÁ¾ ¿ëµµ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

À¯Çüº°·Î, ½ÃÀåÀº ¾ËÆÄ ¹æ»çü, º£Å¸ ¹æ»çü, ±ÙÁ¢ Á¶»ç ¿ä¹ý ¾ÆÀ̼ÒÅäÇÁ·Î ºÐ·ùµË´Ï´Ù. ¥â¹æ»çü ºÎ¹®Àº Àå°Å¸® À̵¿, Àú¿¡³ÊÁö ¼öÁØ, ÀÌ¿ô ¼¼Æ÷¿¡ ´ëÇÑ ÇØ°¡ Àû±â ¶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿ëµµº°·Î º¼ ¶§ ½ÃÀåÀº ½ÉÀ庴ÇÐ, »À ½ºÄµ, Æó ½ºÄµ, Á¾¾çÇÐ, ½Å°æÇÐ, °©»ó¼± ÀûÀÀ, °ñÀüÀÌ µîÀ¸·Î ³ª´¹´Ï´Ù. Á¾¾çÇÐ ºÐ¾ß´Â ¼¼°è ¾ÏÀÇ À¯º´·ü »ó½ÂÀ¸·Î ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» À̲ø °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÖÁ¾ ¿ëµµ¿¡ µû¶ó ¾÷°è´Â º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ¾Ï ¿¬±¸ ±â°üÀ¸·Î ³ª´¹´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È º´¿øÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº ¾Ï À¯º´·ü Áõ°¡¿Í º´¿ø ¼ö Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.

Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

Áö¿ªÀûÀ¸·Î, ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« °¢ Áö¿ªÀ¸·Î ÆÛÁ® ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ºñÁî´Ï½º¸¦ Àü°³ÇÏ´Â ±¹°¡¿¡ µû¶ó ´õ ³ª´¹´Ï´Ù. ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå Á¡À¯À²ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå È®´ë´Â ¾Ï, ½ÉÇ÷°ü µî ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ¾Ï ÇùȸÀÇ Ãß°è¿¡ µû¸£¸é, 2022³â¿¡´Â ¹Ì±¹¿¡¼­ »õ·Ó°Ô 190¸¸¸íÀÇ ¾Ï ȯÀÚ°¡ Áø´ÜµÇ¾î, 60¸¸9360¸íÀÌ ¾ÏÀ¸·Î »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ, Àü¼úÇÑ Åë°è´Â ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå - °æÀï ±¸µµ:

½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Novartis AG, Bracco Imaging SpA, Bayer AG, Cardinal Health Inc., Mallinckrodt plc., Lantheus Medical Imaging Inc. GE Healthcare, Eckert &Ziegler, Curium Pharma, International Isotopes Idaho, Inc., Medi Co. ÀÌµé ±â¾÷Àº Á¦Ç° Ãâ½Ã, È®´ë, ÅõÀÚ, Çù¾÷ µîÀ» Æ÷ÇÔÇÏ¿© ½ÃÀåÀÇ ÃÖ´ë Á¡À¯À²À» ¾ò±â À§ÇØ ´Ù¾çÇÑ Àü·«À» äÅÃÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå °³¿ä

  • Á¶»ç ¹üÀ§
  • ½ÃÀåÃßÁ¤³â

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ºÐ¼®
  • °æÀï ÀλçÀÌÆ®

Á¦3Àå Ä¡·á¿ë ÇÙÀÇÇÐÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ½ÃÀåÀÇ ¹Ì·¡ µ¿Çâ

Á¦4Àå Ä¡·á¿ë ÇÙÀÇÇÐ »ê¾÷ ¿¬±¸

  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ¼ºÀå Àü¸Á ¸ÊÇÎ
  • ±ÔÁ¦ Ʋ ºÐ¼®

Á¦5Àå Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

  • COVID-19 ÀÌÀüÀÇ ¿µÇ⠺м®
  • COVID-19 ÀÌÈÄÀÇ ¿µÇ⠺м®

Á¦6Àå Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå »óȲ

  • Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • ÁÖ¿ä Á¦Á¶¾÷üº° ºÐ¼® µ¥ÀÌÅÍ
    • ±âÁ¸ ±â¾÷ÀÇ ºÐ¼®
    • ½ÅÈï±â¾÷ÀÇ ºÐ¼®

Á¦7Àå Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå - À¯Çüº°

  • °³¿ä
    • À¯Çüº° ºÎ¹® Á¡À¯À² ºÐ¼®
    • ¾ËÆÄ ¹æ»çü
    • ¥â¹æ»çü
    • ±ÙÁ¢Á¶»ç¿ä¹ý ¾ÆÀ̼ÒÅäÇÁ

Á¦8Àå Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå- ¿ëµµº°

  • °³¿ä
    • ¿ëµµº° ºÎ¹® Á¡À¯À² ºÐ¼®
    • ½ÉÀ庴ÇÐ
    • »À ½ºÄµ
    • Æó ½ºÄµ
    • Á¾¾çÇÐ
    • ½Å°æÇÐ
    • °©»ó¼±ÀÇ ÀûÀÀÁõ
    • °ñÀüÀÌ
    • ±âŸ

Á¦9Àå Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå - ÃÖÁ¾ ¿ëµµº°

  • °³¿ä
    • ÃÖÁ¾ ¿ëµµº° ºÎ¹® Á¡À¯À² ºÐ¼®
    • º´¿ø
    • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
    • ¾Ï ¿¬±¸±â°ü

Á¦10Àå Ä¡·á¿ë ÇÙÀÇÇÐ ½ÃÀå-Áö¿ª

  • ¼Ò°³
  • ºÏ¹Ì
    • °³¿ä
    • ºÏ¹Ì ÁÖ¿ä Á¦Á¶¾÷ü
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • °³¿ä
    • À¯·´ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ·¯½Ã¾Æ
    • ³×´ú¶õµå
    • ½º¿þµ§
    • Æú¶õµå
    • ±âŸ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç(APAC)
    • °³¿ä
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ÁÖ¿ä Á¦Á¶¾÷ü
    • Àεµ
    • Áß±¹
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • ű¹
    • Àεµ³×½Ã¾Æ
    • Çʸ®ÇÉ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • °³¿ä
    • ¶óƾ¾Æ¸Þ¸®Ä« ÁÖ¿ä Á¦Á¶¾÷ü
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • °³¿ä
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÁÖ¿ä Á¦Á¶¾÷ü
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ÅÍŰ
    • ¾ËÁ¦¸®
    • ÀÌÁýÆ®
    • ±âŸ

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - Ä¡·á¿ë ÇÙÀÇÇÐ ¾÷°è

  • °æÀï ´ë½Ãº¸µå
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Novartis AG
    • Bracco Imaging SpA
    • Bayer AG
    • Cardinal Health Inc.
    • Mallinckrodt plc.
    • Lantheus Medical Imaging Inc.
    • GE Healthcare
    • Eckert &Ziegler
    • Curium Pharma
    • International Isotopes Idaho, Inc.
    • Medi-Radiopharma Co., Ltd.

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

BJH 24.05.23

REPORT HIGHLIGHT

Therapeutic Nuclear Medicine Market size was valued at USD 1,232 Million in 2023, expanding at a CAGR of 4.5% from 2024 to 2032.

The special properties of radioactive elements (radioisotopes) are utilized in therapeutic nuclear medicine (radionuclide treatment) to irradiate cells and/or organs. A radiopharmaceutical is usually injected or consumed in modest amounts to enter the body. Certain organs or tissues are drawn to the radiopharmaceutical. The radioisotopes release radiation, or tiny amounts of energy, from their positions within the body, which acts on target cells and/or organs. This radiation can be used as a palliative measure (e.g., for bone pain), a curative measure (e.g., thyroid cancer), or to decrease the function of an organ (e.g., overactive thyroid).

Therapeutic Nuclear Medicine Market- Market Dynamics

Increasing prevalence of chronic disease to propel market demand

There is a significant global increase in the prevalence of chronic diseases, including cancer, respiratory, neurological, and metabolic problems, as well as cardiovascular disease. According to the Lymphoma Research Foundation, lymphoma is the most frequent cancer among adults and children in the United States, accounting for over a million diagnoses annually. The Global Burden of Diseases reports that heart disease is one of the leading causes of death, accounting for approximately 18 million deaths in 2018. Additionally, approximately 35 million people suffer from heart-related conditions, which is driving up demand for therapeutic nuclear medicines.

Therapeutic Nuclear Medicine Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.5% over the forecast period (2024-2032)

Based on type segmentation, the Beta Emitters segment is expected to dominate the market over the forecast period

Based on the application segmentation, the Oncology segment is expected to lead the market growth during the forecast period

Based on end user segmentation, the Hospitals segment is expected to hold the largest market share over the projected period

Based on region, North America was the leading revenue generator in 2023

Therapeutic Nuclear Medicine Market- Segmentation Analysis:

The Global Therapeutic Nuclear Medicine Market is segmented based on Type, Application, End User, and Region.

Based on the type, the market is categorized into Alpha Emitters, Beta Emitters and Brachytherapy Isotopes. The Beta Emitters segment is expected to dominate the market over the forecast period due to long distance travel, low energy levels, and less harm to nearby cells.

Based on the application, the market is divided into Cardiology, Bone Scans, Pulmonary Scans, Oncology, Neurology, Thyroid Indications, Bone Metastasis and Others. The Oncology segment is expected to lead the market growth during the forecast period due to the rise in the prevalence of cancer across the globe.

Based on the end user, the industry is divided into Hospitals, Ambulatory Surgical Centres and Cancer Research Institutes. The Hospitals segment is expected to hold the largest market share over the projected period. The segment growth is attributable to increase in the prevalence of cancer and increase in the number of hospitals.

Therapeutic Nuclear Medicine Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to hold the majority of market share during the forecast period. The regional market expansion is attributed to the growing prevalence of chronic disease such as cancer, cardiovascular and others. For instance, in 2022, there will be an anticipated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States, according to the American Cancer Society's estimates. Thus, the aforementioned stats drive the market growth.

Therapeutic Nuclear Medicine Market- Competitive Landscape:

The key players in the market are Novartis AG, Bracco Imaging S.p.A, Bayer AG, Cardinal Health Inc., Mallinckrodt plc., Lantheus Medical Imaging Inc., GE Healthcare, Eckert & Ziegler, Curium Pharma, International Isotopes Idaho, Inc. and Medi-Radiopharma Co., Ltd. These players adopted various strategies such as product launch, expansion, investment, collaboration, and others to obtain the maximum market share of the market.

Recent Developments:

In March 2022, Prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC), which has spread to other parts of the body (metastatic), is a type of advanced cancer that Novartis announced the US Food and Drug Administration (FDA) had approved for treatment. PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) was previously known as 177Lu-PSMA-617. Other anticancer treatments (inhibition of the androgen receptor pathway and taxane-based chemotherapy) have already been administered to these individuals.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL THERAPEUTIC NUCLEAR MEDICINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Novartis AG

Bracco Imaging S.p.A

Bayer AG

Cardinal Health Inc.

Mallinckrodt plc.

Lantheus Medical Imaging Inc.

GE Healthcare

Eckert & Ziegler

Curium Pharma

International Isotopes Idaho, Inc.

Medi-Radiopharma Co., Ltd.

GLOBAL THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Alpha Emitters
  • Beta Emitters
  • Brachytherapy Isotopes

GLOBAL THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Cardiology
  • Bone Scans
  • Pulmonary Scans
  • Oncology
  • Neurology
  • Thyroid Indications
  • Bone Metastasis
  • Others

GLOBAL THERAPEUTIC NUCLEAR MEDICINE MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Ambulatory Surgical Centres
  • Cancer Research Institutes

GLOBAL THERAPEUTIC NUCLEAR MEDICINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1.Therapeutic Nuclear Medicine Market Overview

  • 1.1.Study Scope
  • 1.2.Market Estimation Years

2.Executive Summary

  • 2.1.Market Snippet
    • 2.1.1.Therapeutic Nuclear Medicine Market Snippet by Type
    • 2.1.2.Therapeutic Nuclear Medicine Market Snippet by Application
    • 2.1.3.Therapeutic Nuclear Medicine Market Snippet by End User
    • 2.1.4.Therapeutic Nuclear Medicine Market Snippet by Country
    • 2.1.5.Therapeutic Nuclear Medicine Market Snippet by Region
  • 2.2.Competitive Insights

3.Therapeutic Nuclear Medicine Key Market Trends

  • 3.1.Therapeutic Nuclear Medicine Market Drivers
    • 3.1.1.Impact Analysis of Market Drivers
  • 3.2.Therapeutic Nuclear Medicine Market Restraints
    • 3.2.1.Impact Analysis of Market Restraints
  • 3.3.Therapeutic Nuclear Medicine Market Opportunities
  • 3.4.Therapeutic Nuclear Medicine Market Future Trends

4.Therapeutic Nuclear Medicine Industry Study

  • 4.1.PEST Analysis
  • 4.2.Porter's Five Forces Analysis
  • 4.3.Growth Prospect Mapping
  • 4.4.Regulatory Framework Analysis

5.Therapeutic Nuclear Medicine Market: COVID-19 Impact Analysis

  • 5.1.Pre-COVID-19 Impact Analysis
  • 5.2.Post-COVID-19 Impact Analysis
    • 5.2.1.Top Performing Segments
    • 5.2.2.Marginal Growth Segments
    • 5.2.3.Top Looser Segments
    • 5.2.4.Marginal Loss Segments

6.Therapeutic Nuclear Medicine Market Landscape

  • 6.1.Therapeutic Nuclear Medicine Market Share Analysis, 2023
  • 6.2.Breakdown Data, by Key Manufacturer
    • 6.2.1.Established Players' Analysis
    • 6.2.2.Emerging Players' Analysis

7.Therapeutic Nuclear Medicine Market - By Type

  • 7.1.Overview
    • 7.1.1.Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2.Alpha Emitters
    • 7.1.3.Beta Emitters
    • 7.1.4.Brachytherapy Isotopes

8.Therapeutic Nuclear Medicine Market - By Application

  • 8.1.Overview
    • 8.1.1.Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 8.1.2.Cardiology
    • 8.1.3.Bone Scans
    • 8.1.4.Pulmonary Scans
    • 8.1.5.Oncology
    • 8.1.6.Neurology
    • 8.1.7.Thyroid Indications
    • 8.1.8.Bone Metastasis
    • 8.1.9.Others

9.Therapeutic Nuclear Medicine Market - By End User

  • 9.1.Overview
    • 9.1.1.Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 9.1.2.Hospitals
    • 9.1.3.Ambulatory Surgical Centres
    • 9.1.4.Cancer Research Institutes

10.Therapeutic Nuclear Medicine Market- By Geography

  • 10.1.Introduction
    • 10.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2.North America
    • 10.2.1.Overview
    • 10.2.2.Therapeutic Nuclear Medicine Key Manufacturers in North America
    • 10.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4.North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5.North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.6.North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.7.U.S.
      • 10.2.7.1.Overview
      • 10.2.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3.U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4.U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.7.5.U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.8.Canada
      • 10.2.8.1.Overview
      • 10.2.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3.Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4.Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.8.5.Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.Europe
    • 10.3.1.Overview
    • 10.3.2.Therapeutic Nuclear Medicine Key Manufacturers in Europe
    • 10.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4.Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5.Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.6.Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.7.Germany
      • 10.3.7.1.Overview
      • 10.3.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3.Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4.Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.7.5.Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.8.Italy
      • 10.3.8.1.Overview
      • 10.3.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3.Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4.Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.8.5.Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.9.United Kingdom
      • 10.3.9.1.Overview
      • 10.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3.United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4.United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.9.5.United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.10.France
      • 10.3.10.1.Overview
      • 10.3.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3.France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4.France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.10.5.France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.11.Russia
      • 10.3.11.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2.Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3.Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.11.4.Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.12.Netherlands
      • 10.3.12.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2.Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3.Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.12.4.Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.13.Sweden
      • 10.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2.Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3.Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.13.4.Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.14.Poland
      • 10.3.14.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2.Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3.Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.14.4.Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.15.Rest of Europe
      • 10.3.15.1.Overview
      • 10.3.15.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3.Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4.Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.15.5.Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.Asia Pacific (APAC)
    • 10.4.1.Overview
    • 10.4.2.Therapeutic Nuclear Medicine Key Manufacturers in Asia Pacific
    • 10.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4.Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5.Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.6.Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.7.India
      • 10.4.7.1.Overview
      • 10.4.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3.India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4.India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.7.5.India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.8.China
      • 10.4.8.1.Overview
      • 10.4.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3.China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4.China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.8.5.China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.9.Japan
      • 10.4.9.1.Overview
      • 10.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3.Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4.Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.9.5.Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.10.South Korea
      • 10.4.10.1.Overview
      • 10.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3.South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4.South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.10.5.South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.11.Australia
      • 10.4.11.1.Overview
      • 10.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3.Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4.Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.11.5.Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.12.Thailand
      • 10.4.12.1.Overview
      • 10.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3.Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4.Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.12.5.Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.13.Indonesia
      • 10.4.13.1.Overview
      • 10.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3.Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4.Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.13.5.Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.14.Philippines
      • 10.4.14.1.Overview
      • 10.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3.Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4.Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.14.5.Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.15.Rest of APAC
      • 10.4.15.1.Overview
      • 10.4.15.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3.Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4.Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.15.5.Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5.Latin America
    • 10.5.1.Overview
    • 10.5.2.Therapeutic Nuclear Medicine Key Manufacturers in Latin America
    • 10.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4.Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5.Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.6.Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.7.Brazil
      • 10.5.7.1.Overview
      • 10.5.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3.Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4.Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.7.5.Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.8.Mexico
      • 10.5.8.1.Overview
      • 10.5.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3.Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4.Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.8.5.Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.9.Argentina
      • 10.5.9.1.Overview
      • 10.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3.Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4.Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.9.5.Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.10.Colombia
      • 10.5.10.1.Overview
      • 10.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3.Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4.Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.10.5.Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.11.Rest of LATAM
      • 10.5.11.1.Overview
      • 10.5.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3.Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4.Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.11.5.Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.Middle East and Africa
    • 10.6.1.Overview
    • 10.6.2.Therapeutic Nuclear Medicine Key Manufacturers in Middle East and Africa
    • 10.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4.Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5.Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.6.Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.7.Saudi Arabia
      • 10.6.7.1.Overview
      • 10.6.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3.Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4.Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.7.5.Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.8.United Arab Emirates
      • 10.6.8.1.Overview
      • 10.6.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3.United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4.United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.8.5.United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.9.Israel
      • 10.6.9.1.Overview
      • 10.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3.Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4.Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.9.5.Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.10.Turkey
      • 10.6.10.1.Overview
      • 10.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3.Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4.Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.10.5.Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.11.Algeria
      • 10.6.11.1.Overview
      • 10.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3.Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4.Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.11.5.Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.12.Egypt
      • 10.6.12.1.Overview
      • 10.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3.Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4.Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.12.5.Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.13.Rest of MEA
      • 10.6.13.1.Overview
      • 10.6.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3.Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4.Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.13.5.Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11.Key Vendor Analysis- Therapeutic Nuclear Medicine Industry

  • 11.1.Competitive Dashboard
  • 11.2.Company Profiles
    • 11.2.1.Novartis AG
    • 11.2.2.Bracco Imaging S.p.A
    • 11.2.3.Bayer AG
    • 11.2.4.Cardinal Health Inc.
    • 11.2.5.Mallinckrodt plc.
    • 11.2.6.Lantheus Medical Imaging Inc.
    • 11.2.7.GE Healthcare
    • 11.2.8.Eckert & Ziegler
    • 11.2.9.Curium Pharma
    • 11.2.10.International Isotopes Idaho, Inc.
    • 11.2.11.Medi-Radiopharma Co., Ltd.

12.360 Degree Analyst View

13.Appendix

  • 13.1.Research End Userology
  • 13.2.References
  • 13.3.Abbreviations
  • 13.4.Disclaimer
  • 13.5.Contact Us
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦